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AbsTrACT
background recent randomized clinical trials (rcTs) 
demonstrated the efficacy of mechanical thrombectomy 
using stent-retrievers in patients with acute ischemic 
stroke (ais) with large vessel occlusions; however, it 
remains unclear if these results translate to a real-world 
setting. The TreVO stent-retriever acute stroke (TracK) 
multicenter registry aimed to evaluate the use of the 
Trevo device in everyday clinical practice.
Methods Twenty-three centers enrolled consecutive ais 
patients treated from March 2013 through august 2015 
with the Trevo device. The primary outcome was defined 
as achieving a Thrombolysis in cerebral infarction (Tici) 
score of ≥2b. secondary outcomes included 90-day 
modified rankin scale (mrs), mortality, and symptomatic 
intracranial hemorrhage (sich).
results a total of 634patients were included. Mean 
age was 66.1±14.8 years and mean baseline nih stroke 
scale (nihss) score was 17.4±6.7; 86.7% had an 
anterior circulation occlusion. Mean time from symptom 
onset to puncture and time to revascularization were 
363.1±264.5 min and 78.8±49.6 min, respectively. 
80.3% achieved Tici ≥2b. 90-day mrs ≤2 was achieved 
in 47.9%, compared with 51.4% when restricting the 
analysis to the anterior circulation and within 6 hours 
(similar to recent aha/asa guidelines), and 54.3% for 
those who achieved complete revascularization. The 90-
day mortality rate was 19.8%. independent predictors 
of clinical outcome included age, baseline nihss, use of 
balloon guide catheter, revascularization, and sich.
Conclusion The TracK registry results demonstrate 
the generalizability of the recent thrombectomy rcTs in 
real-world clinical practice. no differences in clinical and 
angiographic outcomes were shown between patients 
treated within the aha/asa guidelines and those treated 
outside the recommendations.
InTroduCTIon
Following the publication of multiple positive 
consecutive randomized clinical trials (RCTs), 
mechanical thrombectomy is now considered the 
standard of care for acute ischemic stroke (AIS) 
due to large vessel occlusion (LVO).1–11 Improved 
patient selection criteria and significant technical 
advances leading to a higher rate of meaningful 
revascularization were the main advances that led 
to a better clinical outcome than the first-genera-
tion thrombectomy devices.12 13
However, RCTs are limited by the restrictive 
nature of study design in many aspects, such as 
inclusion and exclusion criteria, center selection, 
and operator experience; therefore, the results 
may not be generalizable to real-world practice. 
Post-marketing clinical registries allow for more 
inclusive criteria by including a range of clinical 
sites, operators, and varying patient populations, 
which provides valuable information on the gener-
alizability and reproducibility of RCTs and addi-
tional opportunities to explore clinical hypotheses 
for patients treated outside these RCTs.14–16
The first stent-retriever device to be introduced 
to the USA was the Solitaire device, which has 
been shown to be as effective in achieving similar 
revascularization and clinical outcome in real-life 
post-marketing experience. Relatively comparable 
safety and efficacy outcomes were demonstrated in 
the North American Solitaire Acute ischemic stroke 
study (NASA Registry) and other post-marketing 
clinical studies.14–16 However, there is no published 
large-scale post-marketing investigator-initiated 
registry for the second FDA-approved stent-re-
triever, the Trevo device.
The TREVO Stent-Retriever Acute Stroke 
(TRACK) Registry is, to date, the largest inves-
tigator-initiated independent US post-marketing 
registry evaluating the real-life clinical experience 
of the Trevo device in 634 patients with AIS. In 
addition to comparing the results with the TREVO2 
RCT to assess for generalizability, we also evalu-
ated the safety and efficacy in those treated outside 
the AHA/ASA-published endovascular treatment 
guideline.2
MeThods
Twenty-three US centers submitted retrospective 
and prospective data on consecutive patients with 
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AIS treated from March 2013 through August 2015 with the 
Trevo device as the first mechanical thrombectomy treatment 
method to restore blood flow for LVO. Patients aged <18 
years and those who were not treated with Trevo as the first-
pass device were excluded. Sites submitted de-identified patient 
level data (demographic, clinical, procedural, and angiographic). 
Institutional review board approval was obtained at each site. 
Mercy Health St Vincent Hospital (Toledo, Ohio, USA) served 
as the coordinating center for TRACK.
TrACK angiographic and clinical outcomes
The primary angiographic outcome was defined as achieving a 
modified Thrombolysis in Cerebral Infarction (mTICI) score 
of ≥2b  at  the  end  of  the  procedure.9 14 Secondary outcomes 
included revascularization rate (complete revascularization to 
TICI 3), symptomatic intracranial hemorrhage (sICH) on the 
24 hours follow-up head CT, modified Rankin Scale (mRS) score 
and mortality at 90 days. sICH was defined as any parenchymal 
hematoma, subarachnoid hemorrhage, or intraventricular 
hemorrhage associated with worsening of the National Insti-
tutes of Health Stroke Scale (NIHSS) score by ≥4 points within 
24 hours. Primary and secondary outcomes were then compared 
with the TREVO2 trial to assess for reproducibility of the results 
in the TRACK Registry.
The full TRACK cohort was further dichotomized into 
patients who met the AHA/ASA recommendations guidelines2 
(treated ≤6 hours  of  symptoms  onset,  intravenous  tissue  plas-
minogen  activator  (IV-tPA)  (if  eligible),  NIHSS  ≥6,  anterior 
circulation occlusion only (except for ASPECT score, which was 
not collected in the TRACK)) and the non-AHA/ASA population.
statistical analysis
Statistical analyses were performed using JMP V.13 (SAS insti-
tute, Cary, North Carolina, USA). Fisher exact or χ2 tests were 
used for categorical variables and the Student’s t-test/F test for 
continuous variables.
Baseline demographic, angiographic, and clinical outcome 
data were analyzed for the full TRACK cohort and compared 
with TREVO2 data. Key system of care and time metrics were 
presented for the full TRACK cohort. True First Pass Effect 
(tFPE), defined as TICI 3 on the first pass with no use of rescue 
therapy, was also evaluated.
Univariate analysis was also performed between the AHA/ASA 
and non-AHA/ASA groups with the TRACK cohort to compare 
baseline features and angiographic and clinical outcomes. For all 
analyses, variables with a p value ≤0.05 and clinically relevant 
factors were entered into a multivariate stepwise logistic regres-
sion model to determine predictors of clinical outcome and/or 
mortality.
resulTs
Full TrACK cohort results
A total of 634 consecutive patients were enrolled into the 
TRACK Registry (figure 1). Five patients were excluded from the 
final analysis (2 were <18 years of age and 3 were not treated 
with Trevo as the first device).
Demographic and baseline features
Baseline demographics are shown in table 1. Mean baseline 
NIHSS was higher in TREVO2 (18.3±5.3) than in TRACK 
Figure 1 TRACK Registry Flow Chart.
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(17.4±6.7) (p=0.04). TRACK had a significantly lower propor-
tion of patients with diabetes, hyperlipidemia, and smoking 
history. The majority of patients presented with an anterior 
circulation occlusion (86.7%), with less middle cerebral artery 
(MCA) occlusion in TRACK compared with TREVO2 (68.9% 
vs 76%, p=0.0002).
TRACK time metrics
Key time metrics in TRACK are presented in figure 2A and show 
a median last known well to presentation at the treating hospital 
door of 160 min, a door to puncture time of 118 min, and final 
puncture to successful recanalization to TICI ≥2b of 67 min.
The majority of TRACK patients (48%) had their puncture 
within 4.5 hours from onset while 15% had their puncture at 
4.5–6 hours (figure 2B).
Primary angiographic outcomes
The TRACK operator-adjudicated revascularization rates of 
TICI ≥2a, TICI ≥2b, and TICI 3 were significantly higher than 
in TREVO2 (92.8%, 80.3%, 44.5% and 85%, 68%, 14% in 
TRACK and TREVO2, respectively) (table 2).  The  TICI ≥2b 
revascularization rate post-Trevo device use only was 68.8% in 
TRACK versus 68% in TREVO2.
Table 1 Baseline and procedural characteristics of the TRACK Registry compared with TREVO2 and TRACK AHA/ASA and non-AHA/ASA sub-
cohorts
TrACK
(n=629)
n (%)
TreVo2
(n=88)
n (%)
p Value
TrACK versus
TreVo2
TrACK-AhA/AsA 
(n=157)
n (%)
TrACK-non-AhA/AsA 
(n=450)
n (%)
p Value
AhA/AsA versus 
non-AhA/AsA
Demographics
  Age (years), mean (SD) 66.1 (14.8) 67.4 (13.9) 0.24 64.9 (15.5) 66.5 (14.5) 0.24
  Age >80 114 (18.1) NA NA 27 (17.2) 85 (18.9) 0.72
  Gender (female) 305 (48.3) 48 (55) 0.3 71 (45.2) 220 (48.9) 0.46
  Race (white) 424 (68.1) NA NA 101 (64.3) 305 (69.0) 0.09
Vascular risk factors
  Hypertension 473 (75.0) 67 (76) 0.04 124 (79.0) 335 (74.4) 0.28
  Atrial fibrillation 247 (39.2) 42 (48) 0.13 56 (35.7) 184 (41.0) 0.26
  Diabetes mellitus 161 (25.5) 33 (38) 0.02 41 (26.1) 117 (26.0) 1.00
  Hyperlipidemia 314 (49.8) 55 (63) 0.03 76 (48.4) 229 (50.2) 0.64
  Smoking history 154 (24.5) 37 (42) 0.001 40 (25.5) 112 (25.0) 0.92
  Coronary artery disease 146 (29.4) 29 (33) 0.1 35 (28.2) 104 (29.6) 0.82
Clinical presentation
  Baseline mRS (median) (min, max) 0 (0,5) 0 (0,1) 0 (0,1) 0 (0,5)
  Initial NIHSS, mean (SD) 17.4 (6.7) 18.3 (5.3) 0.04 18.0 (5.8) 17.2 (6.9) 0.19
Occlusion site
  All MCA segments 434 (68.9) 67 (76) 0.002 118 (75.2) 298 (66.4) 0.06
  M1 344 (54.6) 53 (60) 0.03 118 (75.2) 209 (70.1) 0.0001
  M2 84 (13.3) 14 (16) 0.5 0 (0) 83 (27.9) 0.0001
  M3 6 (1.0) 0 (0) 0.2 0 (0) 6 (2.0) 0.34
  ICA 100 (15.9) 14 (16) 1.0 39 (24.8) 55 (12.3) 0.0003
  Vertebrobasilar circulation 84 (12.7) 7 (8) 0.2 0 (0) 84 (18.7) 0.0001
  Anterior circulation 546 (86.7) 81 (92) 0.2 157(100) 365 (81.3) 0.0001
Initial systolic BP, mean (SD) 144.9 (26.6) NA NA 145.9 (28.1) 144.7 (26.2) 0.68
Initial diastolic BP, mean (SD) 78.2 (19.2) NA NA 78.6 (20.9) 78.1 (18.6) 0.63
IV tPA 321 (51.2) 51 (58) 0.22 157 (100) 164 (34.9) 0.0001
Hospital transfer 315 (50.0) NA NA 62 (39.5) 237 (52.8) 0.005
Procedural factors
  Time from onset to puncture (min), mean (SD) 363.1 (264.5) 276 (90) 0.00 217.5 (67.8) 413.8 (287.7) <0.0001
  General anesthesia 394 (62.4) 72 (82) 0.004 89 (56.7) 284 (63.1) 0.2
  Regional aspiration 142 (22.6) NA NA 44 (30.3) 98 (23.6) 0.12
  IA tPA 130 (20.7) NA NA 46 (29.3) 83 (18.5) 0.006
  Balloon guide catheter 298 (47.3) NA NA 84 (53.5) 206 (45.9) 0.08
Bold type indicates statistical significance.
AHA, American Heart Association; ASA, American Stroke Association; ICA, internal carotid artery; mRS, modified Rankin Scale; MCA, middle cerebral artery; NIHSS, National 
Institutes of Health Stroke Scale; tPA, tissue plasminogen activator.
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The mean number of passes in TRACK was 1.9±1.2 
compared with 2.4±1.4 in TREVO2 (p=0.002). The majority 
of TRACK cases (45.6%) were treated using a single device pass. 
Rescue therapy was used in 21.5% of TRACK patients. Opera-
tor-adjudicated rates of distal embolization and embolization into 
new territory in TRACK were 23% and 4.5%, respectively.
Figure 2 TRACK Registry key time metrics and outcomes. (A) Key time metrics. (B) Distribution of patients according to Tme of Onset to Groin 
puncture (TOG) and percentage of good clinical outcome in each stratum. (C) Distribution of 90-day modified Rankin Scale (mRS) scores in the TRACK 
Registry, AHA/ASA, non-AHA/ASA, and true First Pass Effect (tFPE) cohorts. The bar indicates patients with a good clinical outcome (mRS ≤2). tFPE is 
defined as TICI 3 on the first pass with no use of rescue therapy.
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Primary clinical outcomes
Ninety-day clinical outcome data were available in 92% 
(579/629). Good  clinical  outcome  (defined  as mRS ≤2  at  90 
days) was achieved in 48% of TRACK patients (table 2 and 
figure 2C). No difference in sICH rate was observed between 
TRACK and TREVO2. The mortality rate was lower in TRACK 
than in TREVO2 (19.8% vs 33%, p=0.01).
Finally, we assessed the rate of good clinical outcome in 
those who achieved tFPE of TICI 3 without the use of adjunc-
tive therapy (25%). This group achieved a higher rate of good 
clinical outcome (54.3%) than the rate of 48% achieved for the 
overall TRACK cohort (p<0.05) (figure 2C).
Predictors of clinical outcomes
On univariate analysis, the main predictors of good outcome 
(mRS 0–2) were recanalization success, use of balloon guide 
catheter (BGC), and tFPE, and predictors of poor outcome 
(3–6 mRS) included age, NIHSS, hypertension, hyperlipidemia, 
diabetes, procedure time, and sICH (figure 3). However, after 
multivariate adjustment, the variables that remained as inde-
pendent predictors of clinical outcome were age, initial NIHSS, 
BGC, sICH, and tFPE.
Additionally, we performed unadjusted analyses of key clin-
ical and technical factors known to influence mRS. Figure 4A–D 
demonstrates an inverse correlation between clinical outcome 
Table 2 Clinical and angiographic outcomes of the TRACK Registry versus TREVO2, AHA/ASA and non-AHA/ASA sub-cohorts
TrACK (n=629)
n (%)
TreVo2
(n=88) n(%)
p Value TrACK 
versus TreVo2
*TrACK-AhA/AsA 
(n=157) n (%)
*TrACK-non-AhA/AsA
(n=450)
n (%)
*p Value
AhA/AsA 
versus non-
AhA/AsA
Clinical outcome
  mRS ≤2 at 90 days 277 (47.9) 34 (40) 0.2 75 (51.4) 193 (46.7)
Anterior circulation only: 
158/333 (47.5%)
0.34
0.49
  NIHSS at discharge, mean (SD) 17.4 (6.7) NA NA 11.3 (11.3) 11.3 (11.1) 1.00
NIHSS at 90 days, mean (SD) 18.1 (18.7) NA NA 13.7 (16.6) 19.9 (19.3)
Anterior circulation 
only: 18.9 (19)
0.04
0.1
Mortality at 90 days 106 (19.8) 29 (33) 0.01 19 (14.1) 85 (22.2)
Anterior circulation only: 
59 (19.3)
0.05
0.22
sICH 44 (7.1) 4 (4.5) 0.4 8 (5.2) 35 (8.0) 0.28
Angiographic outcomes
  TIMI ≥2 564 (89.7) NA NA 141 (89.8) 400 (89.6) 1.0
  TICI ≥2a 584 (92.8) 73 (85) 0.0004 146 (93.0) 415 (92.9) 1.0
  TICI ≥2b 505 (80.3) 60 (68)* 0.005 128 (81.5) 360 (80.4) 0.81
  TICI 2a 79 (12.6) 19 (22)* 0.004 19 (12.1) 60 (12.7) 0.89
  TICI 2b 225 (35.8) 48 (54)* 0.001 45 (28.7) 180 (38.1) 0.03
  TICI 3 280 (44.5) 12 (14)* <0.05 82 (52.2) 198 (41.9) 0.03
  Distal embolization 112 (23.0) NA NA 24 (19.4) 81 (23.7) 0.38
  Embolization into new territory 20 (4.5) NA NA 10 (8.3) 9 (2.9) 0.042
  No of passes, mean (SD) 1.9 (1.2) 2.4 (1.4) 0.002 2.0 (1.1) 1.9 (1.2) 0.40
  1 272 (45.6) NA NA 61 (41.2) 201 (47.1) 0.22
  2 167 (28.2) NA NA 44 (29.7) 123 (27.5) 0.92
  3 112 (18.8) NA NA 34 (23.0) 78 (17.4) 0.23
  >3 45 (7.5) NA NA 6 (4.1) 36 (8.0) 0.10
  Use of rescue therapy 133 (21.5) 16 (18) 0.48 35 (22.9) 93 (21.0) 0.65
  Type of rescue therapy (65/133)
  Solitaire 29 (44.6)
  IA-tPA 28 (43.1)
  Aspiration 41 (63.1)
  Intracranial angioplasty 15 (23.1)
  Fluoroscopic time (min) 32.3 (22.9) NA NA 31.9 (21.2) 32.8 (23.8) 0.35
  Time of puncture to revascularization or end of 
procedure (min), mean (SD)
78.8 (49.6) NA NA 77.1 (46.8) 79.2 (48.9) 0.64
*Core laboratory adjudicated.
Bold type indicates statistical significance.
AHA, American Heart Association; ASA, American Stroke Association, mRS,  modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; sICH, symptomatic 
intracranial hemorrhage; TICI, Thrombolysis In Cerebral Infarction; tPA, tissue plasminogen activator.
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and age, baseline NIHSS, time to revascularization, and number 
of passes. The highest probability of achieving mRS 0–2 is 
patients of younger age with lower baseline NIHSS, shorter time 
to revascularization, and fewer number of passes, while those 
with advanced age, higher initial NIHSS, longer time to revas-
cularization, and high number of passes had the greatest proba-
bility of achieving an mRS 4–6. These factors did not appear to 
influence the probability of achieving mRS 3.
TrACK AhA and non-AhA subgroups
For the TRACK AHA and non-AHA cohort analysis, 22 cases 
were excluded due to missing data necessary for classification 
based on AHA/ASA guidelines; 157 and 450 patients met the 
criteria for the AHA/ASA and non-AHA/ASA groups, respec-
tively (figure 1).
Baseline variables
Given the exclusivity of anterior circulation lesions in the AHA/
ASA cohort, there was a statistical difference between the AHA/ASA 
and non-AHA/ASA groups in the occlusion location (table 1). Mean 
time from onset to puncture was different between the AHA/ASA 
and non-AHA/ASA groups (217.5±67.8 min vs 413.8±287.7 min, 
p<0.0001). IV-tPA use was 100% versus 34.9% in the AHA/ASA 
and non-AHA/ASA cohorts, respectively. Patient transfer was more 
common in the non-AHA/ASA group (53%, p=0.005). A higher 
rate of IA thrombolytic utilization was noted in the AHA/ASA 
group (29%, p=0.006).
Angiographic and technical outcomes
No difference was observed in revascularization success rates in 
the AHA/ASA and non-AHA/ASA groups (table 2). However, a 
significantly higher rate of TICI 3 was seen in the AHA/ASA 
Figure 3 Forest plot of univariate predictors of clinical outcome dichotomized as mRS 0–2. OR (95% CI) are depicted to the right of the figure. Red 
and black bars indicate variables which are significant.
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cohort. Embolization into new territory was higher in AHA/ASA 
patients (8.3% vs 2.9%, p=0.04).
Clinical outcomes
The  rate  of  good  clinical  outcome  at  90  days  (mRS ≤2) was 
similar between the cohorts but mortality was higher in the 
non-AHA/ASA group (table 2).
dIsCussIon
To date, TRACK is the largest investigator-initiated, real-life, 
post-marketing, clinical registry evaluating a total of 634 subjects 
treated with Trevo as the first device for AIS secondary to LVO. 
Results from the TRACK Registry supported similar angio-
graphic and clinical outcomes as reported in TREVO2 RCTs and 
the NASA Registry.9 10
A unique observation from this real-life registry is that a 
large proportion of patients (74.1%) were treated outside the 
recent AHA/ASA guidelines and recommendations for endovas-
cular therapy. For example, 18.1% in the non-AHA/ASA group 
were >80 years of age and 37% of patients were outside the 
6 hour time window; however, these subgroups still had an 
excellent angiographic and clinical outcome (table 2, figure 2b).
Angiographic outcomes
The final angiographic revascularization outcome (after all 
devices and rescue therapy) of TICI ≥2b was higher in TRACK 
than in TREVO2 (80.3% vs 68%).9 However, when comparing 
the revascularization rate post-Trevo device use only, there was 
no difference between the two cohorts (68.8% in TRACK versus 
68% in TREVO2).9 When compared with the recently published 
randomized trials, the rate of TICI 2b/3 is comparable with the 
Solitaire-treated patients in the SEER pooled analysis (77%) and 
with the HERMES mechanical thrombectomy group (71%).11 12
In our study, we observed a significantly higher proportion 
of patients achieving near complete final revascularization 
to TICI 3 (44.5% final and 37.4% post-Trevo only vs 14% in 
TREVO2).9 The higher rate of near complete revascularization 
may be explained by several factors. (1) In real-life experience 
there is no limit to the number of passes that an operator can 
attempt. (2) The rate of BGC use, proven since the TREVO2 
Figure 4  (A–D) Probability of ordinal modified Rankin Scale (mRS) with key clinical and technical factors. Note the highest probability of mRS 1 
with younger age, lower initial NIHSS, shorter revascularization time, and smaller number of passes; mRS 3 is not a discriminator. An inverse effect 
was noted at the other extremes, with a higher probability of mRS 6 with older age, higher initial NIHSS, longer revascularization time, and higher 
number of passes.
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study to be associated with a higher rate of near complete revas-
cularization, may be higher in the current registry (47.3% in 
TRACK vs 44.1% in NASA, unavailable in TREVO2 study).15 17 
(3) An improvement in operator learning and experience since 
the approval of the device. (4) The combined approach of Trevo 
device with local aspiration from a distal large-bore catheter, 
which was used in approximately 23% of the cases.
Although potential for self-reporting bias of the angiographic 
data is another valid reason for the higher rate of near complete 
revascularization, TREVO2 showed that there was no differ-
ence between operator and core laboratory adjudication of the 
recanalization.9
The self-reported rates of distal embolization and embo-
lization into new territory were similar to those in the NASA 
Registry (23% vs 16.4% and 4.5% vs 5.5%, respectively).10 The 
rate of distal embolization correlated well with those who did 
not achieve TICI 2b or higher, indicating possible persistent 
downstream occlusion. The ability to accurately estimate the 
rate of new embolization is limited by lack of complete baseline 
angiographic assessment or availability of pre-intervention CT 
angiographic data.
Clinical outcome
Despite the high rate of posterior circulation thrombectomy 
(table 1) and percentage of patients who had an onset to puncture 
time >6 hours (figure 2b), the rate of good clinical outcome in 
the TRACK Registry was 47.9%, which compared well with the 
rates in TREVO2 (40%) and with the NASA Registry (42%).9 10
In the TRACK AHA/ASA group the rate of a good clinical 
outcome was 51.4%, which is similar to the rates of good clinical 
outcome noted in the HERMES and SEER pooled analyses (46% 
and 54%, respectively).11 12 The clinical outcome in TRACK was 
also augmented to 54.3% in patients achieving tFPE to TICI 3 
(figure 3), as shown in previous studies.17
The rates of sICH were similar in TRACK (7.1%), TREVO2 
(4.1%), and NASA (9.9%).9 10 The numerical difference in 
hemorrhage rate in TRACK versus TREVO2 may be related 
to a more liberal inclusion of patients with severe strokes and 
those outside the 8 hour time window. When patients with only 
anterior circulation were evaluated, the rate of symptomatic 
hemorrhage decreased to 5.2%, which is similar to the HERMES 
pooled analysis of 4.4%.12
The mortality rate in TRACK was 19.8%, which is lower than 
the reported rate of 33% in NASA.9 10 When examining the 
mortality rate within the AHA/ASA guidelines-like group, the 
mortality rate decreased to 14.4%, which compared well with 
the 15.3% noted with the HERMES pooled analysis.12
Similar to other studies, recanalization, FPE, BGC, and MCA 
clot location predicted a favorable outcome while age, proce-
dure time, symptomatic hemorrhage, initial NIHSS and age were 
predictors of a poor clinical outcome as depicted.18–20
An interesting observation was noted in the ordinal mRS 
outcome of the key predictors of clinical outcome (figure 4). We 
noted a higher likelihood of achieving mRS 1, followed by 2 
then 0 with endovascular therapy, when the predictors favored 
a good outcome (such as shorter onset to puncture time, younger 
age, less severe baseline NIHSS, shorter revascularization time, 
and fewer number of device attempts). mRS 6, followed by 4, 
then 5 (in this order) were more likely to happen when these 
factors were not favorable for a good clinical outcome. Interest-
ingly, mRS 3 was flat with no slope and predication ability across 
all these clinical variables.
Revascularization time (defined as puncture to TICI 2b) 
metrics in TRACK showed a mean time of 78±49.6 min 
compared with 77.1±46.8 min in NASA.10 This may be related 
to individual patient variability between the two studies and may 
be evaluated in the future in an individual patient-level pooled 
analysis. An additional potential explanation is the difference in 
centers participating in the two studies and their system of care 
and local processes.
limitations
TRACK has the inherent limitation of self-reported prospec-
tive and retrospective angiographic and clinical outcome data. 
However, site and core laboratory-reported angiographic 
outcomes in TREVO2 were similar. In addition, including all 
consecutive patients and sample size may have reduced the selec-
tion bias.
Another limitation is the potential lack of precision in our 
reported time metrics due to the retrospective nature of the data, 
which could result in over/underestimation of time metrics (such 
as the door to puncture and revascularization times).
ConClusIon
Our real-life experience with the TREVO device demonstrated 
the ability to mirror the recanalization, safety, and efficacy 
outcomes obtained in the TREVO2, SEER, and HERMES 
randomized clinical studies.
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